Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.
Despite high sequence similarity between NOP (nociceptin/orphanin FQ opioid peptide) and opioid receptors, marked differences in endogenous ligand selectivity, signal transduction, phosphorylation, desensitization, internalization and trafficking have been identified; underscoring the evolutionary difference between NOP and opioid receptors. Activation of NOP receptors affects nociceptive transmission in a site-specific manner, with antinociceptive effects prevailing after peripheral and spinal activation, and pronociceptive effects after supraspinal activation in rodents. The net effect of systemically administered NOP receptor agonists on nociception is proposed to depend on the relative contribution of peripheral, spinal and supraspinal activation, and this may depend on experimental conditions. Functional expression and regulation of NOP receptors at peripheral and central sites of the nociceptive pathway exhibits a high degree of plasticity under conditions of neuropathic and inflammatory pain. In rodents, systemically administered NOP receptor agonists exerted antihypersensitive effects in models of neuropathic and inflammatory pain. However, they were largely ineffective in acute pain while concomitantly evoking severe motor side effects. In contrast, systemic administration of NOP receptor agonists to non-human primates (NHPs) exerted potent and efficacious antinociception in the absence of motor and sedative side effects. The reason for this species difference with respect to antinociceptive efficacy and tolerability is not clear. Moreover, co-activation of NOP and μ-opioid peptide (MOP) receptors synergistically produced antinociception in NHPs. Hence, both selective NOP receptor as well as NOP/MOP receptor agonists may hold potential for clinical use as analgesics effective in conditions of acute and chronic pain.
Department of Translational Science, Global Innovation, Grünenthal GmbH, Aachen, Germany.
W
W
Schröder
D G
DG
Lambert
M C
MC
Ko
T
T
Koch
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D020864:Calcium Channels, N-Type / Q000378:metabolism; D006801:Humans; D010146:Pain / Q000188:drug therapy / Q000378:metabolism*; D020033:Protein Isoforms / Q000378:metabolism; D011957:Receptors, Opioid / Q000819:agonists* / Q000737:chemistry / Q000378:metabolism*; D000094942:Nociceptin Receptor
D000700:Analgesics; D020864:Calcium Channels, N-Type; D020033:Protein Isoforms; D011957:Receptors, Opioid; D000094942:Nociceptin Receptor; C000722283:OPRL1 protein, human